Amgen psoriasis drug tops J&J's Stelara in Phase III study

Nov 11 (Reuters) - Amgen Inc said on Tuesday that its experimental psoriasis drug, brodalumab, met all the goals of a late-stage study, clearing the rough skin patches associated with the disease more thoroughly than Johnson & Johnson's Stelara and a placebo.